Palomino Laboratories (PALX) EBITDA (2023 - 2025)

Palomino Laboratories (PALX) has 3 years of EBITDA data on file, last reported at -$1.6 million in Q3 2025.

• For the quarter ending Q3 2025, EBITDA fell 129958.51% year-over-year to -$1.6 million; the trailing twelve-month figure through Sep 2025 stood at -$1.8 million (down 1436.54% YoY), and the FY2024 full-year result was -$140080.0, down 66.89% from the prior year.
• EBITDA eased to -$1.6 million in Q3 2025, from -$35548.0 in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$1234.0 in Q3 2024 to a low of -$1.6 million in Q3 2025.
• A 3-year average of -$217336.2 and a median of -$35548.0 in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA surged 97.12% in 2024 and slumped 129958.51% in 2025, its largest moves.
• Tracing PALX's EBITDA over 3 years: stood at -$32574.0 in 2023, then slumped by 323.53% to -$137962.0 in 2024, then sank by 1063.31% to -$1.6 million in 2025.
• Business Quant data shows PALX's EBITDA at -$1.6 million in Q3 2025, -$35548.0 in Q2 2025, and -$17828.0 in Q1 2025.